Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



The Use of Ischemia Modified Albumin as a Predictive and Prognostic Biomarker in Patients with Non–Acetaminophen-Induced Acute Liver Failure

Aydıin Aktas,Orgun Gunes,Fatma Olmez Budak,Nilufer Diller,Adem Tuncer,Sami Akbulut,Mehmet Cagatay Taskapan,Cemalettin Aydin,Cuneyt Kayaalp,Sezai Yilmaz.




Abstract
Cited by 0 Articles

Background: King College criteria (KCC) and Model for End-Stage Liver Disease (MELD) score are the most commonly used criteria in the follow-up of patients with acute liver failure (ALF). However, these criteria cannot always predict prognosis and the need for liver transplantation (LT).
Aim: This study aimed to investigate to usability of ischemia modified albumin (IMA) and IMA/albumin ratio (IMAR) values in the follow-up of ALF patients.
Methods: IMA and IMAR values of 23 ALF patients and 43 healthy volunteers were measured. Then IMA and IMAR values were compared with KCC and MELD score to predict LT requirement and prognosis in ALF patients.
Results: IMA and IMAR values were significantly higher in ALF patients compared healthy volunteers (p=0.001, p=0.001; respectively). IMA and IMAR values predicted LT requirement in ALF patients such as KCC and MELD (≥30) score (p=0.006, p=0.04, p=0.001, p=0.03; respectively). IMA values were found to better than KCC in predicting mortality (p=0.008, p=0.02; respectively). MELD (≥30) score failed to predict mortality (p=0.44).
Conclusion: IMA and IMAR values can be used as diagnostic biomarkers in ALF patients. IMA is a better prognostic biomarker in the follow-up of ALF patients.

Key words: Acute liver failure, Liver transplantation, Ischemia modified albumin, Predictive factors, Prognostic factors






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.